Acadia craters as takeover buzz is silenced by (another) NDA delay, CEO exit

John Carroll San Diego-based Acadia Pharmaceuticals put out word on Wednesday evening that it is delaying its expected NDA for pimavanserin from Q1 back to some time in the second half ...

UPDATED: Endo aims to lure Salix from Valeant with $175-per-share offer

Carly Helfand Last month, some industry watchers speculated that the low price Valeant agreed to pay for North Carolina's Salix could leave room for other bids. And now, one has ...

Astellas scores FDA approval for life-threatening fungus-fighter

Carly Helfand The FDA offers incentives for developing products that target life-threatening infections, and Astellas just became the latest drugmaker to take advantage. FiercePharma ...

FDA panel backs Kythera’s double chin-fighting shot

Damian Garde Kythera won the unanimous support of an FDA advisory panel for its fat-busting injection, rolling toward approval with a first-of-its-kind treatment. FierceBiotech News

AcelRx hammered (again) after FDA demands a new Zalviso study after all

John Carroll When the FDA rejected AcelRx's drug/device Zalviso for pain last summer, the biotech said no new trials were required–suggesting it could be back in front of ...

Novartis CEO eyes more cost cuts to satisfy margin demands

Tracy Staton Novartis execs are rolling up their sleeves for another round of cost cuts. "Very significant" cost cuts, CEO Joe Jimenez tells the Financial Times, partly from ...

Astellas bags FDA approval for a new anti-infective

Damian Garde Japanese pharma giant Astellas won FDA approval for an anti-fungal treatment targeting two rare but dangerous infections, the latest drugmaker to take advantage of new ...

Roche neighbors sue, claiming contamination lowered home prices

Carly Helfand Roche handled hazardous chemicals at its now-shuttered facility in Nutley, NJ–and its neighbors say the company didn't do it properly. FiercePharma News
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS